Conatus Pharmaceuticals Inc. (CNAT): Price and Financial Metrics


Conatus Pharmaceuticals Inc. (CNAT): $0.56

0.00 (0.18%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add CNAT to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

CNAT Stock Price Chart Interactive Chart >

Price chart for CNAT

CNAT Price/Volume Stats

Current price $0.56 52-week high $1.07
Prev. close $0.56 52-week low $0.23
Day low $0.54 Volume 1,696,900
Day high $0.59 Avg. volume 1,283,592
50-day MA $0.38 Dividend yield N/A
200-day MA $0.37 Market Cap 18.44M

Conatus Pharmaceuticals Inc. (CNAT) Company Bio


Conatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines to treat liver diseases in the United States. The company was founded in 2005 and is based in San Diego, California.


CNAT Latest News Stream


Event/Time News Detail
Loading, please wait...

CNAT Latest Social Stream


Loading social stream, please wait...

View Full CNAT Social Stream

Latest CNAT News From Around the Web

Below are the latest news stories about Conatus Pharmaceuticals Inc that investors may wish to consider to help them evaluate CNAT as an investment opportunity.

Intercept (ICPT) Gains 7.5% YTD on Progress in NASH Space

Intercept (ICPT) stock gains as it becomes the forerunner in the NASH drug race.

Yahoo | December 2, 2019

NASH Scorecard Year to Date: The Winners and the Losers

NASH sees a highly rewarding market with candidates of blockbuster potential. Let us take a look at the hits and misses in this space so far this year.

Yahoo | November 29, 2019

Conatus Pharmaceuticals Appoints Kathy Scott as Independent Board Member

SAN DIEGO, Nov. 18, 2019 -- Conatus Pharmaceuticals Inc. (NASDAQ: CNAT) today announced the appointment of Kathleen D. Scott to the Conatus Board of Directors as an additional.

Yahoo | November 18, 2019

Conatus Pharmaceuticals (CNAT) Reports Q3 Loss, Misses Revenue Estimates

Conatus (CNAT) delivered earnings and revenue surprises of 16.67% and -48.06%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | November 6, 2019

Conatus Pharmaceuticals Reports Third Quarter 2019 Financial Results

SAN DIEGO, Nov. 05, 2019 -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced financial results for the quarter and nine months ended September 30, 2019. Recent.

Yahoo | November 5, 2019

Read More 'CNAT' Stories Here

CNAT Price Returns

1-mo N/A
3-mo N/A
6-mo N/A
1-year N/A
3-year -32.93%
5-year -89.17%
YTD N/A
2021 N/A
2020 0.00%
2019 -76.88%
2018 -62.55%
2017 -12.33%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.4781 seconds.